Navigation Links
GeneNews launches world's first blood test for colorectal cancer screening
Date:7/21/2008

ill result in better decision making by doctors and their patients regarding next steps in the colorectal cancer screening process and ultimately help identify the presence of this cancer in patients at a curable stage."

"More than 21,500 Canadians will be diagnosed with colorectal cancer this year and most of them will not have exhibited any symptoms. The most effective method for prevention and early detection of colorectal cancer is through widespread screening of individuals," said Barry D. Stein, President of the Colorectal Cancer Association of Canada. "A patient-friendly blood test like ColonSentry(TM) is welcomed and can certainly contribute to increased compliance with screening programs. This will facilitate earlier detection and treatment of the disease, resulting in improved outcomes for patients with colorectal cancer."

"Ideally, colorectal cancer screening should proceed in a programmatic fashion that begins with risk stratification based on the results from an initial test and then continues with proper follow up based on findings," said Dr. Bernard Levin, an internationally recognized expert in colorectal cancer screening and Chair of the Company's Colorectal Cancer Clinical Advisory Board. "As the initial test, the convenience of a blood test to assess current risk could encourage more individuals to undergo screening, leading to earlier detection of colorectal cancer thereby reducing suffering and death."

"More than 1.5 million people in the GTA meet the eligibility guidelines for colorectal cancer screening, making this an ideal location for the initial launch of ColonSentry(TM). We are building our commercial organization and look forward to subsequent planned launches of ColonSentry(TM) in Asia, the United States and Europe," said Dr. Heiner Dreismann, interim CEO and Lead Director of GeneNews. "Achieving this most significant milestone well on target reflects the deep commitment of the entire GeneNews staff and the timely d
'/>"/>

SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GeneNews announces management changes to support commercialization of ColonSentry(TM)
2. Genenews adds two members to its Board of Directors
3. GeneNews Announces First Quarter Results
4. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
5. GeneNews announces 2007 year end results
6. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
7. GeneNews receives ISO 13485 accreditation
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
10. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
11. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Synthetic protein mimics structure, function of metalloprotein in nature 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 1Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 4Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 5Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 6Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 7Study Links Epilepsy to Brain Protein 57562 1Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 1Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 2Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 3Long time QHR Hospital Client Cary Medical Center Recognized with Top Leadership Team Award 57558 4